Viatris, Inc. (VTRS)
|Net Income (ttm)||760.80M|
|Ex-Dividend Date||Aug 23, 2022|
|Day's Range||10.50 - 10.75|
|52-Week Range||9.45 - 15.60|
|Price Target||14.51 (+37.0%)|
|Earnings Date||Aug 8, 2022|
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent... [Read more...]
In 2021, Viatris's revenue was $17.89 billion, an increase of 49.73% compared to the previous year's $11.95 billion. Losses were -$1.27 billion, 89.4% more than in 2020.Financial Statements
According to 21 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price forecast is 14.51, which is an increase of 37.02% from the latest price.
Viatris Inc. (NASDAQ: VTRS) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year. Michael Goettler, CEO of Viatris, said that because of strong operatio...
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Reports Total Revenues of $4.12 Billion; U.S. GAAP Net Earnings of $314 Million; Adjusted EBITDA of $1.48 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million; and Free Cash Flow...
Even over the last month, when the S&P 500 has rallied for an 8% gain, Viatris shares have continued their downwards trajectory, declining 5.5% in value.
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are these dividend payments at risk?
Billionaires are taking advantage of the weakness in Pfizer and Viatris this year.
These stocks pay a dividend yield of more than 4%.
PITTSBURGH , July 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief ...
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
Lower share prices won't stop them from hiking their dividends.
The company reported improved net income and free cash flow in the last quarter.
These stocks are incredibly cheap, and aren't as risky as their low multiples suggest they might be.
PITTSBURGH , May 20, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Co...
PITTSBURGH , May 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021 achievements and prog...
Viatris Inc (NASDAQ: VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Li...
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.